STOCK TITAN
  1. Home
  2. Sec-filings
  3. INO
  4. [Form 4] INOVIO PHARMACEUTICALS, INC. Insider Trading Activity

INOVIO (INO) Chief Scientific Officer reports RSU vesting, tax withholding and new stock option awards

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

INOVIO PHARMACEUTICALS Chief Scientific Officer Laurent Humeau reported routine equity-compensation activity. On May 20, 2026, 6,027 restricted stock units vested, and 2,163 common shares were withheld at $1.23 per share to cover tax obligations, leaving him with 48,986 common shares held directly. He also received new awards of 27,440 restricted stock units and 34,160 stock options with a $1.73 exercise price, scheduled to vest in equal annual installments from February 26, 2027 through February 26, 2029.

Positive

  • None.

Negative

  • None.
Insider Humeau Laurent
Role Chief Scientific Officer
Type Security Shares Price Value
Exercise Restricted Stock Unit 6,027 $0.00 --
Grant/Award Common Stock Option 34,160 $0.00 --
Grant/Award Restricted Stock Unit 27,440 $0.00 --
Exercise Common Stock 6,027 $0.00 --
Tax Withholding Common Stock 2,163 $1.23 $3K
Holdings After Transaction: Restricted Stock Unit — 12,054 shares (Direct, null); Common Stock Option — 34,160 shares (Direct, null); Common Stock — 48,986 shares (Direct, null)
Footnotes (1)
  1. Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 18,081 restricted stock units was as follows: 6,027 shares vested on May 20, 2026; 6,027 shares will vest on May 20, 2027; 6,027 shares will vest on May 20, 2028. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in the immediately preceding row and described in footnote (1) herein. The stock option grant was approved by Inovio's Board of Directors on March 4, 2026, subject to shareholder approval of the amendment and restatement of the Amended and Restated 2023 Omnibus Incentive Plan under which the stock options were granted. Inovio's shareholders approved the amendment and restatement of the Amended and Restated 2023 Omnibus Incentive Plan on May 20, 2026. The vesting schedule for the options granted on May 20, 2026 was as follows: 11,387 shares will vest on February 26, 2027; 11,387 shares will vest on February 26, 2028; 11,386 shares will vest on February 26, 2029. Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the restricted stock units granted on May 20, 2026 was as follows: 9,147 shares will vest on February 26, 2027; 9,147 shares will vest on February 26, 2028; and 9,146 shares will vest on February 26, 2029. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. The restricted stock units were approved by Inovio's Board of Directors on March 4, 2026, subject to shareholder approval of the amendment and restatement of the Amended and Restated 2023 Omnibus Incentive Plan under which the restricted stock units were granted. Inovio's shareholders approved the amendment and restatement of the Amended and Restated 2023 Omnibus Incentive Plan on May 20, 2026.
Shares withheld for taxes 2,163 shares at $1.23 Tax withholding on RSU vesting May 20, 2026
RSUs vested 6,027 units Restricted stock units vested May 20, 2026
Common shares held after transactions 48,986 shares Direct ownership after May 20, 2026 activity
New RSU grant 27,440 units Granted May 20, 2026, vesting 2027‑2029
New stock option grant 34,160 options at $1.73 Granted May 20, 2026, expire May 20, 2036
Unvested RSUs remaining 12,054 units RSU balance after 6,027-unit vesting event
Future RSU vesting tranches 9,147 / 9,147 / 9,146 units Vesting on Feb 26, 2027, 2028, 2029
Future option vesting tranches 11,387 / 11,387 / 11,386 options Option vesting on Feb 26, 2027, 2028, 2029
Restricted Stock Unit financial
"Each restricted stock unit represents a contingent right to receive one share of common stock."
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
tax withholding obligations financial
"represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations"
stock option grant financial
"The stock option grant was approved by Inovio's Board of Directors on March 4, 2026"
Omnibus Incentive Plan financial
"under which the stock options were granted. Inovio's shareholders approved the amendment and restatement of the Amended and Restated 2023 Omnibus Incentive Plan"
An omnibus incentive plan is a single, flexible program a company uses to give employees and executives different types of pay tied to performance — for example stock options, restricted shares, cash bonuses and other awards — all governed by one set of rules. It matters to investors because it determines how many new shares may be created, how leaders are motivated and how much the company will spend on compensation over time; think of it as a master toolbox that affects both costs and the total share supply.
derivative security financial
"Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Humeau Laurent
(Last)(First)(Middle)
C/O INOVIO PHARMACEUTICALS, INC.
6769 MESA RIDGE RD.
(Street)
SAN DIEGO CALIFORNIA 92121
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
INOVIO PHARMACEUTICALS, INC. [ INO ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Scientific Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/20/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/20/2026M6,027A(1)48,986D
Common Stock05/20/2026F2,163(2)D$1.2346,823D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Unit(1)05/20/2026M6,027 (1) (1)Common Stock6,027$012,054D
Common Stock Option$1.7305/20/2026(3)A34,160 (4)05/20/2036Common Stock34,160$034,160D
Restricted Stock Unit(5)05/20/2026(6)A27,440 (5) (5)Common Stock27,440$027,440D
Explanation of Responses:
1. Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 18,081 restricted stock units was as follows: 6,027 shares vested on May 20, 2026; 6,027 shares will vest on May 20, 2027; 6,027 shares will vest on May 20, 2028. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.
2. The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in the immediately preceding row and described in footnote (1) herein.
3. The stock option grant was approved by Inovio's Board of Directors on March 4, 2026, subject to shareholder approval of the amendment and restatement of the Amended and Restated 2023 Omnibus Incentive Plan under which the stock options were granted. Inovio's shareholders approved the amendment and restatement of the Amended and Restated 2023 Omnibus Incentive Plan on May 20, 2026.
4. The vesting schedule for the options granted on May 20, 2026 was as follows: 11,387 shares will vest on February 26, 2027; 11,387 shares will vest on February 26, 2028; 11,386 shares will vest on February 26, 2029.
5. Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the restricted stock units granted on May 20, 2026 was as follows: 9,147 shares will vest on February 26, 2027; 9,147 shares will vest on February 26, 2028; and 9,146 shares will vest on February 26, 2029. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.
6. The restricted stock units were approved by Inovio's Board of Directors on March 4, 2026, subject to shareholder approval of the amendment and restatement of the Amended and Restated 2023 Omnibus Incentive Plan under which the restricted stock units were granted. Inovio's shareholders approved the amendment and restatement of the Amended and Restated 2023 Omnibus Incentive Plan on May 20, 2026.
Remarks:
/s/ Laurent Humeau05/21/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did INO Chief Scientific Officer Laurent Humeau report?

Laurent Humeau reported RSU vesting, tax-share withholding, and new equity awards. 6,027 restricted stock units vested, 2,163 shares were withheld for taxes, and he received 27,440 new RSUs plus 34,160 stock options as compensation.

How many INOVIO (INO) shares does Laurent Humeau hold after these transactions?

After the reported transactions, Laurent Humeau directly holds 48,986 shares of INOVIO common stock. He also has 12,054 restricted stock units outstanding and 34,160 stock options that may convert into additional shares if they vest and are exercised.

Were Laurent Humeau’s INOVIO Form 4 transactions open-market buys or sells?

The Form 4 shows no open-market buys or sells. Activity reflects RSU vesting, tax withholding of 2,163 shares, derivative exercises, and grants of 27,440 restricted stock units and 34,160 stock options as part of his equity compensation.

What new equity awards did INOVIO grant to Laurent Humeau on May 20, 2026?

INOVIO granted Laurent Humeau 27,440 restricted stock units and 34,160 stock options at a $1.73 exercise price. Both awards vest in three annual tranches on February 26, 2027, 2028, and 2029, subject to the described vesting schedules.

How are Laurent Humeau’s new INOVIO stock options structured and when do they expire?

The stock options cover 34,160 shares at a $1.73 exercise price and were granted under INOVIO’s 2023 Omnibus Incentive Plan. They vest in three annual installments through February 26, 2029 and expire on May 20, 2036 if not exercised.